



# A medical device-grade T1 and ECV phantom for global T1 mapping quality assurance—the T1 Mapping and ECV Standardization in cardiovascular magnetic resonance (T1MES) program

## Citation

Captur, G., P. Gatehouse, K. E. Keenan, F. G. Heslinga, R. Bruehl, M. Prothmann, M. J. Graves, et al. 2016. "A medical device-grade T1 and ECV phantom for global T1 mapping quality assurance—the T1 Mapping and ECV Standardization in cardiovascular magnetic resonance (T1MES) program." *Journal of Cardiovascular Magnetic Resonance* 18 (1): 58. doi:10.1186/s12968-016-0280-z. <http://dx.doi.org/10.1186/s12968-016-0280-z>.

## Published Version

doi:10.1186/s12968-016-0280-z

## Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:29407603>

## Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

## Share Your Story

The Harvard community has made this article openly available.  
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

RESEARCH

Open Access



# A medical device-grade T1 and ECV phantom for global T1 mapping quality assurance—the T<sub>1</sub> Mapping and ECV Standardization in cardiovascular magnetic resonance (T1MES) program

Gabriella Captur<sup>1,2,3,20†</sup>, Peter Gatehouse<sup>4†</sup>, Kathryn E. Keenan<sup>5</sup>, Friso G. Heslinga<sup>6,7</sup>, Ruediger Bruehl<sup>8</sup>, Marcel Prothmann<sup>9</sup>, Martin J. Graves<sup>10</sup>, Richard J. Eames<sup>11</sup>, Camilla Torlasco<sup>12</sup>, Giulia Benedetti<sup>13</sup>, Jacqueline Donovan<sup>14</sup>, Bernd Ittermann<sup>8</sup>, Redha Boubertakh<sup>15</sup>, Andrew Bathgate<sup>16</sup>, Celine Royet<sup>16</sup>, Wenjie Pang<sup>16</sup>, Reza Nezafat<sup>17</sup>, Michael Salerno<sup>18</sup>, Peter Kellman<sup>19</sup> and James C. Moon<sup>2,3,20\*</sup>

## Abstract

**Background:** T<sub>1</sub> mapping and extracellular volume (ECV) have the potential to guide patient care and serve as surrogate end-points in clinical trials, but measurements differ between cardiovascular magnetic resonance (CMR) scanners and pulse sequences. To help deliver T<sub>1</sub> mapping to global clinical care, we developed a phantom-based quality assurance (QA) system for verification of measurement stability over time at individual sites, with further aims of generalization of results across sites, vendor systems, software versions and imaging sequences. We thus created T1MES: The T<sub>1</sub> Mapping and ECV Standardization Program.

**Methods:** A design collaboration consisting of a specialist MRI small-medium enterprise, clinicians, physicists and national metrology institutes was formed. A phantom was designed covering clinically relevant ranges of T<sub>1</sub> and T<sub>2</sub> in blood and myocardium, pre and post-contrast, for 1.5 T and 3 T. Reproducible mass manufacture was established. The device received regulatory clearance by the Food and Drug Administration (FDA) and Conformité Européenne (CE) marking.

**Results:** The T1MES phantom is an agarose gel-based phantom using nickel chloride as the paramagnetic relaxation modifier. It was reproducibly specified and mass-produced with a rigorously repeatable process. Each phantom contains nine differently-doped agarose gel tubes embedded in a gel/beads matrix. Phantoms were free of air bubbles and susceptibility artifacts at both field strengths and T<sub>1</sub> maps were free from off-resonance artifacts. The incorporation of high-density polyethylene beads in the main gel fill was effective at flattening the B<sub>1</sub> field. T<sub>1</sub> and T<sub>2</sub> values measured in T1MES showed coefficients of variation of 1 % or less between repeat scans indicating good short-term reproducibility. Temperature dependency experiments confirmed that over the range 15–30 °C the short-T<sub>1</sub> tubes were more stable with temperature than the long-T<sub>1</sub> tubes. A batch of 69 phantoms was mass-produced with random sampling of ten of these showing coefficients of variations for T<sub>1</sub> of 0.64 ± 0.45 % and 0.49 ± 0.34 % at 1.5 T and 3 T respectively.

(Continued on next page)

\* Correspondence: j.moon@ucl.ac.uk

†Equal contributors

<sup>2</sup>NIHR University College London Hospitals Biomedical Research Center, Maple House Suite, Tottenham Court Road, London W1T 7DN, UK

<sup>3</sup>Barts Heart Center, St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK

Full list of author information is available at the end of the article



© 2016 The Author(s). **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

(Continued from previous page)

**Conclusion:** The T1MES program has developed a  $T_1$  mapping phantom to CE/FDA manufacturing standards. An initial 69 phantoms with a multi-vendor user manual are now being scanned fortnightly in centers worldwide. Future results will explore  $T_1$  mapping sequences, platform performance, stability and the potential for standardization.

**Keywords:**  $T_1$  mapping, Standardization, Phantom,

## Background

Myocardial tissue characterisation by  $T_1$  mapping and estimation of extracellular volume (ECV) by cardiovascular magnetic resonance (CMR) is playing an increasingly important role in the diagnosis and management of patients and clinical trials [1].  $T_1$  mapping is available as three broad classes of sequences, on multiple platforms, at two field strengths. Factors influencing  $T_1$  mapping stability and inter-sequence comparisons are well understood [1–4] but little is known about  $T_1$  mapping delivery at a larger scale over many sites and there is no global quality assurance (QA) system.

The goal of the T1MES program (T1 Mapping and Extracellular volume Standardisation) was to construct an optimised phantom for QA of myocardial  $T_1$  mapping, covering a relevant range of  $T_1$  values with suitable  $T_2$  values for the tissues modelled. The proposed QA consists of regular scans using fixed  $T_1$ -mapping protocols identical to whatever fixed protocols are used in vivo at each participating site. We therefore aimed for a phantom design that would have stable  $T_1$  values for as long as possible. We also aimed for a phantom design avoiding temperature sensitivity of its  $T_1$  values as explained later in Methods.

Such a QA system would form part of a system for optimal mapping precision and accuracy [2] within the increasingly known fundamental limitations of the  $T_1$  mapping methods [5, 6].

The  $T_1$  Mapping and ECV Standardization (T1MES) program therefore aimed to:

1. Create a partnership of physicists, clinicians and national metrology institutes
2. Design phantom systems for 1.5 T and 3 T for any manufacturer/sequence reflecting  $T_1$  values in myocardium and blood, pre- and post-Gadolinium-based contrast agents (GBCA)
3. Reproducibly specify and mass produce phantoms with a rigorously repeatable process and to regulatory standards
4. Distribute them to global CMR sites with detailed instructions for fortnightly scanning
5. Publish full details of the formulation to encourage additional applications
6. Measure confounders (e.g. temperature dependency)
7. Analyse scans over 1 year to study the stability of  $T_1$  measurements over time at each scanner, including a temperature correction model for  $T_1$
8. Curate phantom data long-term in an open access repository available for reuse/analysis
9. Analyse the inter-site differences in  $T_1$  values and explore the deliverability of a technique-independent ' $T_1$ /ECV Standard' through local calibration

To date we have achieved steps 1 to 6 of this process, namely the development, testing, certification, QA protocol and preliminary results of T1MES. This paper summarises these first 6 milestones.

## Methods

### Definitions


The term “phantom” refers to the complete test object (Fig. 1).

The term “tube” refers to each of the small bottles embedded within the phantom.

The “gel matrix” is the gel and bead mixture filling the phantom that surrounds all of the tubes.

### Collaboration process

A design collaboration for developing and testing the T1MES phantom and its prototypes was established, consisting of clinicians, physicists, national metrology institutes (the US National Institute of Standards and Technology [NIST] and the German Physikalisch-Technische Bundesanstalt [PTB]) and a small-medium enterprise familiar with phantom production (Resonance Health [RH], Perth, Australia). Funding was secured including a grant from the European Association of Cardiovascular Imaging. Time and expertise was provided for free by the partnership. To engage a global community with constrained funding, the phantoms were gifted (first come, first served) to centers with the proviso that they: a) scan them fortnightly for 1 year and upload the results; b) engage with the partnership to explore any unexpected results; c) do not do anything that could potentially compromise (a) or (b) (e.g. deconstruct the phantom object); and d) give proper reference to the T1MES project if they use the phantoms for other purposes.



**Fig. 1** Internal and external phantom structure. Internal (3 T, looking at the front—**a**) and external (1.5 T, front and back—**b**) T1MES phantom structure. The nine tubes are supported on a translucent resin base composed of unsaturated polyester/styrene. A careful hardening and curing process ensured a smooth surface finish for the resin base. The front of the phantom (**b left**) contains an isocenter cross label to aid positioning as well as an LCD thermometer. Careful positioning of the bottle on the scanner table (**c**) with the cap towards its head end is needed to ensure it is scanned at isocenter each time. HDPE = high-density polyethylene; LCD = liquid crystal display; NiCl<sub>2</sub> = Nickel Chloride; PE = polyethylene; PVC = poly vinyl chloride

### Phantom design


The design process involved several prototype iterations (known as models A—D before the final mass-production of E-models). Some aspects such as artefacts from the prototype A through D-models that guided the final E-model design are described in Methods and in Fig. 2 with a timeline in Fig. 3. At the very least, the initial A-D models were needed to achieve reasonable  $T_1$  and  $T_2$  values without deleterious imaging artefacts, especially as imaging was conducted remotely from the manufacturer.

The range of  $T_1$  and  $T_2$  values in the phantom aims to cover typical native and post-GBCA values in both myocardium and blood. The especially wide range of  $T_1$  post-GBCA (due to variable practice regarding dose, wash-out delays etc. and of course also disease) requires several tubes to cover it. From a review of published values and our own experience, we selected the values listed. Whatever rationale is adopted, with a limited number of tubes there will inevitably be gaps.

$T_1$  is generally longer at 3 T compared to 1.5 T. Initially we aimed to design a single phantom for both 1.5 T and 3 T, containing a sufficient number of tubes to cover the needed  $T_1$  ranges in blood and myocardium, with suitable  $T_2$  values, pre and post-GBCA at both field strengths. However, the frequency dispersion (i.e.  $B_0$  field dependence) of relaxation times in the phantoms differed strongly from that of myocardium and blood, particularly for the long pre-GBCA tubes, requiring a total

of 13 different tubes for 1.5 T and 3 T. Fitting 13 tubes into a single phantom would either have made the object 'large' (in relation to the  $B_1$  distortion at 3 T discussed below) or would have required the use of smaller calibre tubes. The following considerations justify our construction therefore of 'field-specific' phantoms:

- Tubes had to be a minimum of 20 mm diameter so regions of interest (arbitrarily set to 13 mm) would exclude in-plane imaging artifacts at the boundaries between tubes related to the use of clinical  $T_1$  mapping protocols with coarse image resolution, mostly based on single-shot imaging (e.g. Gibbs artifact at the edge of tubes [Fig. 2d] or the potential impact of filtering against it applied differently by various protocol parameters). Altering protocols to optimise phantom scanning would be inconsistent with the aim of the project. The true resolution achieved is further convoluted by the use of asymmetric frequency-encoded readouts for faster repetition time (TR) in balanced steady-state free precession (bSSFP) imaging or partial-phase-encode sampling for shorter total shot duration, and to some extent also by signal variation during the shot.
- Embedding tubes into a gel-filled phantom is important for three reasons: 1) to permit sufficient signal for scanner calibrations; 2) to minimise  $B_0$




**Fig. 2** Artifact examples in earlier prototypes (a–g) and final T1MES phantom (i, j). Four earlier prototypes (models A–D) were rejected before the final model. **a** Coronal image of the earlier A-model (aqueous fill) showing bright artifacts around the tubes resulting from bSSFP going off-resonance that would have led to variations in T1 values by MOLLI and similar sequences. **b** Transverse image of A-model showing the characteristic ‘cat’s head’ artifact of air-bubbles trapped in the paramagnetically doped aqueous tubes. Significant off-resonance artifact is also noticeable in the central tubes. **c** Another coronal image through A-model but with larger gaps between tubes showing the combined effect of motion artifact (due to the aqueous fill) and  $B_0$  distortion. **d** Transverse image of C-model attempting to use narrower tubes to pack 12 instead of 9, but significant Gibbs artifact can be seen in each tube. **e** Transverse image of C-model showing three small dark circular artifacts (12, 3 and 9 o’clock positions) caused by glue used to stabilize the tube arrangement. We subsequently switched to silicone-based glues that were less likely to trap air bubbles and were artifact-free. **f** Severe stabilisation artifact appearing as a thick dark band around the border of a D-model—here the phantom was scanned immediately after being received from the courier company and the bottle was still very cold from the transportation. Additionally susceptibility artifacts can be seen as thin linear bands spoiling some of the tubes (9 and 3 o’clock). **g** Significant image intensity inhomogeneity during a D-model test session on a GE scanner caused by accidental omission of the folded blanket, intended to separate the phantom bottle from the anterior chest coil. **h** Curved tube artifact and dark rings arising from ink printed onto the sides of digestive tubes (images courtesy of K. E. Keenan and NIST). **i** Coronal bSSFP localiser image and **j** typical T<sub>1</sub> map of a final 3 T T1MES phantom obtained by MOLLI using a bSSFP readout on a Siemens 3 T Skyra scanner. bSSFP = balanced steady-state free precession; MOLLI = modified Look-Locker inversion recovery. Other abbreviation as in Fig. 1

and  $B_1$  field distortions local to each tube; and 3) for greater thermal stability. However, embedding all the 13 tubes (to cover 1.5 T and 3 T values) into a single phantom (whether water or water-based gel-filled) will have increased its overall dimensions making it harder to make (our tests and others [7, 8] show that  $B_1$  homogeneity across large ROIs could not be achieved especially at 3 T). Alternative oil-based phantoms have a smaller dielectric permittivity, useful for weaker radiofrequency (RF) displacement current distortion of  $B_1$ , but the chemical shift of the matrix fill would require

embedded tubes also to use oil-based chemistry (as in diffusion phantoms). Alkanes or similar [9] could not deliver the required range of T<sub>1</sub> and T<sub>2</sub> (written as T<sub>1</sub>|T<sub>2</sub>) and a predominately single-peak nuclear magnetic resonance (NMR) spectrum, with the required temperature stability. By using separate water-based gel-filled phantoms for 1.5 T and 3 T with the known high permittivity of water, at a size large enough to fit the needed tubes there was still significant  $B_1$  distortion (range of different flip angles achieved for a prescribed protocol nominal flip-angle) but we were able to counteract it using a method described later.





**Fig. 3** Prototype models and T1MES project timeline. CE = Conformité Européenne; FDA = Food and Drug Administration; GE = General Electric; NIST = US National Institute of Standards and Technology; PTB = German Physikalisch-Technische Bundesanstalt; QA = quality assurance; RH = Resonance Health

- This project aims to provide quality assurance for clinically used  $T_1$  protocols without adapting to the phantom (e.g. no switching to spoiled-gradient echo, or using shorter-TR, no alterations of resolution or field of view etc.; see Additional file 1). Clinical  $T_1$  mapping protocols are sensitive to off-resonance effects for various well-known reasons. Therefore,  $B_0$  distortion near any of the tubes needed to be minimised (tests showed how tube alignment with the  $B_0$  direction was best—this data not shown).

#### Phantom materials

All materials proposed for phantoms to date suffer different deficiencies. We adopted the most suitable formulation known, which are paramagnetically doped agarose or carrageenan gels [10, 11]. Some of the main design aspects are listed in Table 1.

Agarose or similar gel phantoms are widely used in MR research but less often in commercial phantoms, probably because of long-term stability issues discussed later. Gels permit independent variation of  $T_1/T_2$  and they avoid fluid movement within image slice during long inversion recovery (IR) times that could potentially introduce uncertainty in the  $T_1^*$  to  $T_1$  conversion [12]. A more concentrated gelling agent mainly shortens  $T_2$ ; a higher paramagnetic ion concentration mainly shortens  $T_1$  [11, 13]—the two effects are not independent but can be modelled [14] enabling design of mixtures with any required  $T_1/T_2$  combination. We did not include sodium

chloride (NaCl) (see  $B_1$  uniformity section below). Gel choices include carrageenan, gelatin, agar-agar, polyvinyl alcohol, silicone, polyacrylamide. Some have undesirable NMR spectral properties. The paramagnetic ion choice [15] includes copper, cobalt, iron, manganese ( $Mn^{2+}$ ), gadolinium and nickel ( $Ni^{2+}$ ). Due to the individual  $T_1/T_2$  relaxivities of the various ions, no currently known ionic mixture in water can deliver the native myocardial  $T_1/T_2$  combination (which requires a relatively high  $T_1$  with a short  $T_2$ ).  $Ni^{2+}$  was our first choice as the paramagnetic relaxation modifier at it is less temperature and frequency dependent than other ions [13, 16] and because nickel chloride ( $NiCl_2$ ) agarose gel phantoms have been shown to be stable over a 1 year period [17].

#### Characterization of $T_1$ and $T_2$ dependence on agarose and nickel

To achieve the required  $T_1/T_2$  tube values we characterised the relation between  $T_1/T_2$ , agarose and  $NiCl_2$  concentrations. We made a wide variety of test mixtures as follows: we dissolved at 95 °C for 2.5 h, 135 different concentrations of  $NiCl_2$ , water and agarose, each in a separate 50 ml digestive tube. Using a preheated serological pipette, samples were transferred into preheated NMR tubes (to prevent instant setting of the gel while flowing down the tube), allowed to set and analysed at a measuring temperature of 22 °C with a 1.4 T Bruker Minispec mq60 (60 MHz) relaxometer (Perth, Western Australia). Exponential fitting was done and  $T_1$  and  $T_2$

**Table 1** Design factors when developing a  $T_1$  mapping phantom

Design factor	Explanation	Our proposed solution
Bottle magnetostatics and $B_0$ distortion	The ideal phantom would be uniform and ellipsoidal to avoid susceptibility-induced magnetostatic field perturbation. Such a phantom would permit sphere of Lorentz uniformity but this is not easily mass produced. Many phantoms are cylindrical with the long axis along the static field, $B_0$ but there is usually off-resonance at the z-ends of such objects [7].	An outer phantom body with a smooth surface and soft rounded-edges, placed inside $B_0$ still distorts some of the imposed magnetic field lines at its z-ends so we prescribed scanning halfway along the length of the bottle.
Long term gel stability and risk of moulding	Phantoms with long-term stability could assure the stability of methods applied to patients against scanner alternations and across multiple centers.	Moulding was prevented by aseptic manufacturing, the toxicity of $Ni^{2+}$ ions, and the absence of nutrients in the type of agarose used. Tap water might contain microbial contamination and metal ions so high purity water was used. The main risk is from contraction of gel on loss of water leading to gaps and water condensation but $NiCl_2$ -doped agarose gel phantoms can be stable over a 1-year period [17].
Seal, leakages, air trapping for aqueous fill	Air pockets in the agarose gel phantom will give rise to susceptibility artifacts on account of the large mismatch in static magnetic susceptibility between air and surrounding gel producing a local distortion in magnetic field strength.	The main phantom was sealed by a black polypropylene screw cap fitted with a polyethylene foam insert. Each internal digestive tube was sealed by a tight screw cap. Gel preparation with warm, degassed water reduced air bubble formation. Note the tube “base-upward” setting procedure and subsequent “top-up” of the contracted gel in each tube after setting, described in the text.
Adjustments of $B_0$ and reference frequency	Adjustments of $B_0$ and scanner reference frequency over the phantom have the ability to impact $T_1$ estimates.	We specified a constant shim volume for each scan. This is manufacturer-dependent—see the T1MES manual [23]. Consistency between repeat scans is the main point.
Gel diamagnetism	In the T1MES model system, because the impact of the paramagnetic ions is so small, we can conceptually treat the main phantom box as if it had no tubes, as if it were just filled with uniform gel throughout	The T1MES system has partly paramagnetic and partly diamagnetic constituents, but the impact of the paramagnetic $Ni^{2+}$ ions is small, around 10 % (because concentrations are small) so the overall interaction is diamagnetic, considering the ~9 parts per million diamagnetism of most tissues relative to air from Lenz electronic diamagnetism.
Gibbs artifact ringing and other inplane effects	Truncating artifacts appear as lines of alternating brightness and darkness in the read-out and phase encode direction. Some effects also from asymmetric readout and $k_y$ coverage.	Large diameter digestive tubes to house the 9 agarose doped solutions, so that central regions of each tube are sufficiently distant (a number of pixels away) from regions impacted by artifacts from abrupt signal intensity transitions at the tube edges.
1.4 T, 1.5 T, 3 T performance	Many paramagnetic relaxation modifiers, including $Mn^{2+}$ and $Cu^{2+}$ , exhibit significant frequency dependence.	We used $Ni^{2+}$ [13].
$T_1 T_2$ ranges: blood/myocardium, pre/post-GBCA	The $T_1 T_2$ values were carefully modelled for native and post-gadolinium based contrast agent, blood and myocardium.	5 common tubes, 4 tubes specific to 1.5 T, 4 tubes specific to 3 T. There was no macromolecular addition (no magnetisation transfer modelling) [22].
Tube arrangement	The phantom corners are more prone to inhomogeneities of the $B_0$ and $B_1$ magnetic fields.	Longer $T_1$ tubes were placed nearer the middle of the phantom layout and avoided the corners.

$Cu^{2+}$  copper ions,  $Mn^{2+}$  manganese ions,  $Ni^{2+}$  nickel ions,  $NiCl_2$  nickel chloride

recorded. Based on these results we calibrated the equations [14] modelling the relationship between ingredients and  $T_1|T_2$  relaxation times (omitting saline). The model assumes a linear relation between the ingredients and the relaxation rates  $(R_1, R_2) = (1/T_1, 1/T_2)$ . Using this the ingredients for any required  $T_1|T_2$  tube could be calculated. The model was tested for the set of 13 unique  $T_1|T_2$  combinations desired for the 1.5 T and 3 T phantoms. Some iterations (models A through D, Fig. 3) were required to derive from the model (based on a non-imaging 60 MHz relaxometer) tube values applicable to clinical 1.5 T and 3 T MR systems described later.

### **$B_0$ uniformity**

The approximately cuboid, outer body of the T1MES  $NiCl_2$ -agarose gel phantom (Fig. 1a) consisted of a short, hollow, wide necked and leakproof brown-transparent poly vinyl chloride bottle with a melting temperature of 140 °C (Series #310-73353, Kautex Textron GmbH & Co. KG, Bonn, Germany). The adopted shape is more ellipsoidal than many of the shapes rejected in our tests, consistent with basic magnetostatics (sphere of Lorentz) at 1.5 T and 3 T. The  $B_0$  distortion by the phantom arises from electronic diamagnetism and is not significantly affected by the paramagnetic ion concentrations used. Adding sufficient paramagnetic material to cancel

the diamagnetism and flatten  $B_0$  would excessively shorten the relaxation times.

The final body shape gave sufficient  $B_0$  uniformity for  $T_1$  mapping over only a small region approximately half-way along its length when aligned coaxially with  $B_0$ . Regions towards the cap and base of this object were subject to off-resonance errors [18]. The tubes inside the phantom were therefore not fixed directly down to the base of the main bottle. A 20 mm layer of non-coloured (non-saturated) polystyrene resin (Diggers Casting and Embedding Resin 500GM, #FIE00506-9311052000759, Recochem Inc. Perth, Western Australia) was first set hard in the base of the main bottle, and the tubes were adhered to the top of this layer, so that the tubes occupied the middle of the phantom in the cap-to-base direction, where the  $B_0$  field is optimally uniform.  $B_0$  uniformity was mapped to evaluate this cause of distorted  $T_1$  estimates, using a multi-echo gradient echo sequence based on the phase difference between known echo times [19]. A frequency range of  $\pm 50$  Hz across the phantom was regarded as acceptable based on published  $T_1$ -mapping sensitivity to off-resonance [18].

#### **$B_1$ uniformity**

$B_1$  uniformity in large water-based phantoms [20, 21] is complex but fundamentally the electric dipole moment of the water molecule rotates in the oscillating electric field associated with the RF  $B_1$  field, giving rise to displacement current. Sucrose or other large nonionic molecules can reduce water permittivity, by in effect diluting the problematic water molecules. However, the spectral contribution of such molecules at the high concentrations required is a severe complication. An alternative approach often described in phantom literature is the addition of sodium chloride or similar simple ionic solutes (n.b. not to be confused with high permittivity of powdered titanates, suspended in deuterated water). This tackles the problem from a different direction as it leaves the permittivity unchanged but increases the conductivity ( $\sigma$ ) instead, to reduce  $\omega\epsilon/\sigma$ , i.e. the ratio of displacement current to conduction current. Adding NaCl to the T1MES phantom acted on  $B_1$  distortion at a shallower depth in the T1MES phantom and did not cancel the overall  $B_1$  curvature at any NaCl concentration tested.

In this work, deriving from the sucrose approach, we hypothesised that mixing plastic beads into the matrix gel might also effectively dilute the dielectric permittivity of water and lead to improved  $B_1$  uniformity without directly altering the outer matrix gel  $T_1|T_2$  values (see Table 2, 846 ms | 141 ms). Our choice of outer matrix gel  $T_1|T_2$  values was informed by tests looking at different outer matrix gel  $T_1|T_2$  combinations (data not shown) and their impact on bSSFP-stabilisation artifacts at both field strengths. For the beads, two different kinds

of plastic bead were evaluated: highly monosized microbeads composed of crosslinked poly methyl-methacrylate (PMMA) polymer (6  $\mu$ m, Spheromers, Microbeads AS, Norway) and high-density polyethylene (HDPE) beads of oblate spheroidal form (3 mm polar axis by 4.2 mm equatorial diameter) consisting of smooth, semi-translucent, colourless HDPE with a melt index  $>60$  °C (HDPE Marlex HHM 5502 BN, Chevron Phillips Chemical Company LP, Texas, USA). It is important to control the supply of HDPE pellets to ensure that they have not been reground, rebled or otherwise modified. The two different plastic bead versions of T1MES matrix gel were compared to the use of sucrose or sodium chloride (formulations tested: (1) added to 1050 ml of  $\text{Ni}^{2+}$ -doped gelling solution, separately and in combination = 800 g sucrose, 50 g NaCl; (2) added to 1000 ml of distilled water containing  $\text{NiCl}_2$  and  $\text{MnCl}_2$  with  $T_1 \sim 600$  ms,  $T_2 \sim 170$  ms: 5 g NaCl; (3) added to 2534 ml of distilled water: 1 g, 4 g, 6.5 g, 11.5 g, 14 g, 19 g, 21.5 g NaCl).  $B_1$  homogeneity was evaluated by flip angle (FA) maps derived by the double angle method using FA 60° and 120° ( $\theta_1, 2\theta_1$ ) by long TR (8 s) scanning using a 4 ms duration sinc ( $-3\pi$  to  $+3\pi$ ) slice excitation width to minimise error due to FA variation through the slice.

#### **Temperature dependence of $T_1$ and $T_2$**

Temperature dependency experiments on  $T_1|T_2$  values [15] were carried out at various stages:

**Test 1:** Performed at the PTB laboratory in June 2015 on a 3 T prototype-D (whole phantom with 9 tubes) across 17 temperatures between 14.9 °C and 32.0 °C for  $T_1$  and across 6 temperatures between 15.6 °C and 31.1 °C for  $T_2$ . Each measurement was repeated twice (with a 2 day gap) and made using a 3 T Siemens Magnetom Verio system (VB17) and a 12-channel head coil.

**Test 2:** Performed at the NIST laboratory in November 2015 on six loose tubes from the final production run of E-model phantoms.  $T_1|T_2$  were measured at 9.9, 17.1, 20.1, 23.1 and 30.1 °C on an Agilent 1.5 T small bore scanner in a temperature-controlled environment. Temperatures were measured using a fiber optic probe.  $T_1$  was measured by inversion-recovery spin echo (IRSE) (TR [s] = 10, inversion time [TI, ms] = 50, 75, 100, 125, 150, 250, 500, 1000, 1500, 2000, 3000) and  $T_2$  by SE (TR [s] = 10, TE [echo time, ms] = 15, 30, 60, 120, 240, 480, 960). Note that some of the data acquired under short-term reproducibility was obtained in support of temperature Test 2.

#### **Short-term reproducibility**

Short-term reproducibility (single site, single manufacturer, single sequence) aided temperature sensitivity work and



**Table 2** List of  $T_1/T_2$  values for the target 13 tubes and outer matrix gel and the required agarose/ $\text{NiCl}_2$  concentrations for the final phantom

Description target ( <i>Tube ID</i> )	$T_1$ (ms at 1.4 T <sup>a</sup> )	$T_2$ (ms at 1.4 T <sup>a</sup> )	Agarose (%)	$\text{NiCl}_2$ (mM)
"Short" post-GBCA blood (A)	256	172	0.244	5.547
"Normal" native blood 1.5 T (B)	1490	282	0.373	0.362
"Long" post-GBCA blood (C)	427	212	0.325	2.860
"Short" native myocardium 1.5 T (D)	818	54	2.214	1.231
"Long" native myocardium 1.5 T (E)	1384	57	2.279	0.461
"Medium" native myocardium 1.5 T (F)	1107	56	2.256	0.725
"Short" post-GBCA myocardium (G)	295	50	2.174	4.510
"Long" post-GBCA myocardium (H)	557	51	2.377	2.103
"Medium" post-GBCA myocardium (I)	429	50	2.306	2.942
"Normal" native blood 3 T (J)	1870	288	0.388	0.180
"Short" native myocardium 3 T (K)	1043	56	2.245	0.858
"Long" native myocardium 3 T (L)	1510	55	2.289	0.342
"Medium" native myocardium 3 T (M)	1279	56	2.273	0.531
Outer matrix gel fill	846	141	0.780	1.155

<sup>a</sup>By Bruker minispec mq60 relaxometer 1.4 T (22 °C) at Resonance Health laboratory, Australia  
 GBCA gadolinium-based contrast agents, ID identity number

assessed baseline variability between fortnightly scans with all other parameters constant (not least, temperature). For the final T1MES phantom (E-model) two short-term reproducibility experiments were performed:

**Test 1:** Six loose tubes from the final production run of E-model phantoms were tested for short-term reproducibility of  $T_1/T_2$  values at the NIST laboratory in November 2015, at 20.1 °C on an Agilent 1.5 T small bore scanner.  $T_1$  was measured by IRSE (TR [s] = 10, TE [ms] = 14.75, TI [ms] = 50, 75, 100, 125, 150, 250, 500, 1000, 1500, 2000, 3000) and  $T_2$  by SE (TR [s] = 10, TE [ms] = 14.75, 20, 40, 80, 160).

**Test 2:** One of the final E-model phantoms for 3 T was tested for short-term repeatability of  $T_1/T_2$  values using a Siemens 3 T Skyra at Royal Brompton Hospital in November 2015. This test was performed by removing and repositioning the receiver coil, phantom and its supports on each of ten runs, incurring full readjustment of all scanner setup procedures before each run. The acquired data was ten runs, each containing two repeated  $T_1$  maps, performed at  $20.3 \pm 0.5$  °C. An extension of this work showed that the temperature increase of the T1MES phantom caused by specific absorption rate (SAR) deposition during imaging for repeated  $T_1$  maps was negligible.

#### Detailed construction of phantoms

Some of the detailed construction topics and constraints are listed in Table 1.

Each phantom (1.5 T or 3 T) contains nine tightly capped digestive tubes (#SC475, 50 ml from Environmental

Express, South Carolina, USA) embedded in a gel matrix containing Nickel (II) Chloride hexahydrate (99.9999 % purity grade, Acros Organics, New Jersey USA, n.b. highly hygroscopic), high purity deionized water (Ibis Technology) and polysaccharide agarose powder with low endosmotic flow for electrophoresis (molar ratio  $\leq 0.07$ , Acros Organics).


Mass production was from large batches of 14 solutions (13 tubes + outer matrix gel, Table 2) from which all the tubes and outer containers were filled accordingly. The mass production required some caution against deterioration of the agarose/ $\text{NiCl}_2$  mixtures if kept at high temperatures for periods exceeding around 8 h. The production of all copies of each tube therefore had to be completed within a single working day and as rapidly as possible. Deterioration was noted as a change of agarose gel colour from colourless to faint yellow. Microwave oven heating for initial agarose dissolution was followed by further magnetically-stirred heating and adjustments (based on relaxometry of samples from the mixture). Stirring was essential for uniform gel production into all copies of each tube. Each of the nine tubes is filled with differently doped agarose gels and contains minimal air gaps. Agarose gel contracts as it sets solid, contracting more in stronger agarose mixtures. By "topping up" more gel to the space left by contraction after the initial fill had set in each tube, the air gap can be minimised. Further, by cooling the tubes from the base (by standing them in approximately 2 cm depth of cold water), the gel solidified from the base upward so that contraction left a gap at the top of the tube for adding the "top-up". This practical step was essential to avoid

mid gel contraction gaps forming that is otherwise observed when the gel is allowed to set naturally earlier along the tube sidewalls. Such mid-gel gaps tend to cause a tear down the middle of the gel-filled tube making it unusable for ROI placement in images. The dissolving and solidifying temperatures of agarose gel show hysteresis, dissolving fully only near boiling-point, but requiring cooling to around 45 °C for solidification. The hysteresis assists practically, for example when pouring molten gel around the HDPE beads needed for the main matrix fill.


Of the 18 tubes used in the 1.5 T and 3 T phantoms, 4 are 1.5 T specific, 4 are 3 T specific (because tissue native  $T_1$  is longer at 3 T) and five tubes (the post-GBCA tubes) common to both field strengths (Fig. 4). Although

some difference in post-GBCA  $T_1$  values does occur between 3 T vs. 1.5 T, this difference is absorbed within the very wide range of GBCA doses, post-GBCA times, GBCA types etc. in clinical use. Therefore 13 individual recipes were made. The 9 tubes in each field-specific phantom generate 9 different  $T_1|T_2$  combinations (Fig. 5) modelled to cover the physiological range of native and post-GBCA, blood and myocardium in health and disease. There was no macromolecular addition with no attempt to model magnetisation transfer [22].

After pouring in the resin base, leaving this to set, and adhering the 9 filled tubes on top of this base using ethylene vinyl acetate and polypropylene uncoloured mixture based hotmelt typically applied from a “hot glue



**Fig. 4**  $T_1$  and  $T_2$  values in T1MES.  $T_1$  and  $T_2$  values in the phantom mimic those of myocardium and blood pre and post-GBCA at 1.5 T (Panel **a**) and 3 T (Panel **b**). The 13 relaxometry scopes (refer to Table 2) are explained in the figure. Slow scan reference data for  $T_1|T_2$  is displayed in green (for  $T_1$  by slow IRSE and for  $T_2$  by slow SE, RR interval 900 ms at  $21 \pm 2^\circ\text{C}$ ),  $T_1$  values shown in orange represent the mean value per tube derived from tests on five of the E-model phantoms (using a 5(3)3 256-matrix RR = 900 ms at  $21 \pm 2^\circ\text{C}$  variant of MOLLI adapted for native  $T_1$  mapping; Siemens WIP 448B at 1.5 T and WIP 780B at 3 T), and in blue are  $T_1|T_2$  values obtained by the manufacturer in Australia using a 1.4 T Bruker minispec relaxometer at  $22^\circ\text{C}$ . Tube arrangement is such that long  $T_1$  tubes potentially suffering from more artifacts are kept towards the middle of the phantom and away from the corners. GBCA = gadolinium-based contrast agents; IRSE = inversion recovery spin echo; myo = myocardium; RR = inter-beat interval; SE = spin echo. All  $T_1|T_2$  values are stated in ms. Other abbreviation as in Fig. 2



**Fig. 5**  $T_1$  and  $T_2$  relaxation times versus ingredients at 1.4 T: agarose and  $\text{NiCl}_2$ . Grid represents results of the model. Red points represent single measurements. **a** Longitudinal relaxation time constant ( $T_1$ ), RMSE in  $R_1$  compared to the linear model was  $4.8 \times 10^{-5}$  /ms. **b** Spin–spin relaxation time ( $T_2$ ), RMSE in  $R_2$  compared to the linear model =  $5.3 \times 10^{-4}$  /ms. Since the x and y axes of both fits are comparable, the ingredient that contributes most can be identified. RMSE = root mean square error

gun”, we packed the compact HDPE pellets into the bottle and then poured in the agarose/ $\text{NiCl}_2$  mixture (typically at a temperature  $\sim 50$ – $60^\circ\text{C}$ ) taking care to avoid air pockets from forming in the matrix gel fill.

The T1MES phantom has a volume of 2 l, inner length of 187 mm and inner body cross section 122 mm by 122 mm. The labels show an isocenter cross mark, the correct orientation for positioning it under an anterior chest coil, and a serial number and date of manufacture. Also attached to the outside of the phantom is a liquid crystal display (LCD) thermometer of  $1^\circ\text{C}$  resolution. Notably some pigments used on plastic tubes distort the

magnetic field [12] (Fig. 2h), so all components were tested carefully, rigorously sourced and documented to avoid unexpected changes which could affect future production batches. Even with the efforts to optimise  $B_0$  and  $B_1$  uniformity, some  $T_1|T_2$  combinations are more sensitive to off-resonance errors so these tubes were placed centrally in the phantom avoiding corner locations of greater  $B_0/B_1$  error (explaining the otherwise somewhat counterintuitive ordering of tubes according to their  $T_1$  values).

Production of one phantom took on average 5 h (distributed over batch production not serial manufacture).

As the phantom build was all by manual labour and not automated, it took 3 weeks and four full-time members, 340 h in total to produce the 69 phantoms in this batch.

#### Prototype and production batch testing and quality control

Reproducible manufacturing was established for all tubes. Three prototypes (models A to C) had unsatisfactory  $B_0$  and  $B_1$  uniformities before the satisfactory model-D design. Between June and August 2015, 10 D-model phantoms (five for each of 1.5 T and 3 T) were characterized at ten experienced CMR centers for artifacts and for initial verification of the tube  $T_1|T_2$  values. In September 2015, the final batch of artifact-free (Fig. 2i, j) T1MES phantoms (E-models) were mass-manufactured and shipped to CMR centers worldwide.

All aspects of phantom production conducted at the RH laboratory were performed in accordance with their certified quality management system including the recruitment and training of staff and the quality control checks of final phantoms. Prior to the mass manufacturing, extensive experiments were done in order to setup the standard operation procedures and working instructions to ensure final phantom integrity. Quality control was ensured at three levels: operator level (e.g. careful choice of materials), engineering level (e.g. the responsible process engineer conducted in-production tests/measurements and inspections, such as checks for bubbles in the tubes and bottle seals, and based on the outcome of this analysis, initiated improvement activities) and management level (e.g. by facilitating training and identifying better measurement or production equipment that could be used for future batches). Operator level quality control evaluated phantoms in real-time during the production process through visual inspection to ensure production ran smoothly, predictably, and to the required standards (e.g. by ensuring a flat resin surface, correctly sealed tubes, tight bead packing of the outer matrix gel, etc.). Overall phantom integrity was also visually checked for any production defects prior to shipment (e.g. precise alignment of isocenter cross label correctly offset from the upper surface of the resin base, no distortion of the outer bottle due to excessively hot gel etc.).

Phantom calibration and validation has limitations as phantoms do not fully model tissue (see Discussion). Nonetheless, 'ground truth' values in phantoms were measured using slow scanning 'gold standard' sequences that have previously demonstrated accuracy in phantom work. Of the 69 final E-model phantoms, 10 (14.5 %; 5 at each of 1.5 T and 3 T) underwent 'gold standard' slow  $T_1$  measurements by IRSE (8 TIs from 25–3200 ms) and  $T_2$  measurements by slow SE (8 TEs from 10–640 ms) at a single center (Royal Brompton Hospital; Siemens,


1.5 T Aera and 3 T Skyra; Fig. 6). These slow  $T_1|T_2$  measurements were only performed once and the results used as 'ground truth' for the subsequent measurements. In addition, all tubes were relaxometer-certified pre-assembly.

#### Scanning protocol for T1MES

A fundamental aspect of T1MES was to invite each site to submit phantom data with whichever  $T_1$  mapping sequence they were using clinically. We did not pre-specify any aspect of the  $T_1$  mapping sequence to use, except careful replication of position and phantom setup without any alteration of the parameters used clinically and not to modify any other parameter of the chosen protocolled  $T_1$  mapping method during the period of supplying T1MES repeat scans—i.e. to stick to a fixed protocol (as specified in the JCMR Consensus Guidelines for  $T_1$ /ECV). If changes were inevitable, for example due to scanner upgrades, a method of informing T1MES has been implemented and is described in the manual (Additional file 1). Instructions for adjustment and sizing of the shim volume did need to be vendor-specific and these are explained in the appendix section of the T1MES user manual circulated to all participants.

At all participating T1MES sites, the final phantom is currently scheduled for fortnightly scanning for 1 year using a fixed protocol for inter-scan test-retest analysis. Some centers are additionally scanning the phantom using the same sequence at the same position providing data necessary for short-term intra-scan test-retest analysis. Results from this longitudinal data collection are expected to be published in 2017. The T1MES user manual and QA protocol [23] stipulates that the T1MES phantom be kept in the MR magnet room (for stability and also so that its internal temperature will match that displayed by the surface LCD label) and imaged every 2 weeks for 1 year using consistent coil and phantom arrangement. The T1MES user manual emphasises that image parameters be kept unchanged for serial scans except for automatic adjustments of FA and reference frequency. The user manual specifies the range of acceptable positioning of the phantom in the scanner aligned with the main magnetic field. The phantom is scanned axially halfway along the length of the 9 internal tubes corresponding to halfway along the length of the main bottle, imaging only that slice, to avoid  $z$ -end  $B_0$  distortion. To ensure consistent adjustments of  $B_0$  and scanner reference frequency over the phantom at each repeat scan, the shim volume (also referred to as adjustments volume, adjust region, shim region, shim box) is identically sized and positioned on the phantom bottle for each scan (see Additional file 1). The scan protocol is kept identical for serial scans at each center. Centers were requested to use the same standard anterior chest coil each time.





**Fig. 6** Reference  $T_1/T_2$  values. Variation in the mean  $T_1$  (red dots) and  $T_2$  (blue dots) reference values and standard deviation (whiskers) of the nine tubes averaged for the ten final batch T1MES phantoms that underwent 'gold standard' slow  $T_1$  and  $T_2$  measurements by IRSE and SE respectively at 1.5 T (a) and 3 T (b).  $T_1$  values obtained by MOLLI (5(3)3 [256] (WIP# 448B at 1.5 T and WIP# 780B at 3 T) pre-GBCA sequence (green dots) are also shown. Abbreviations as in Figs. 2 and 4

The minimum fortnightly contribution to T1MES consists of conventional CMR scans: A) the initial localizers; B) at least any one  $T_1$  mapping sequence with simulated electrocardiogram set at 67 beats per minute (inter-beat [RR] interval 900 ms). The T1MES QA program generates three main types of multicenter data: 1) raw data pertaining to long reference scans for  $T_1$  (IRSE) and  $T_2$  (SE) that we reconstruct on receipt; 2) raw  $T_1$  mapping data from some specific centers without the ability to reconstruct their own maps locally, thus we reconstruct the maps on receipt; 3) reconstructed  $T_1/T_2$  maps (majority of sites).  $T_1/T_2$  values were taken as mean values from circular ROIs of fixed diameter, in each of the nine tubes in pixel-wise maps.

Within the network are sites using identical magnets, coils and protocols providing an opportunity for a wide range of inter-sequence and inter-site analyses (scheduled for 2017).

#### Statistics

Statistical analysis was performed in the R programming language (version 3.0.1, The R Foundation for Statistical Computing). Descriptive data are expressed as mean  $\pm$  standard deviation except where otherwise stated. Distribution of data was assessed on histograms and using Shapiro-Wilk test. The coefficient of variation (CoV) between repeated scans was calculated as a measure of reproducibility. For defining the model that describes



the relation between ingredients and relaxation rates ( $R_1|R_2$ ), the fitted parameters were found by fitting a surface for both  $T_1$  and  $T_2$  using the MATLAB (The MathWorks Inc., Natick, MA, USA, R2012b) curvefitting tool and the linear least-squares approach. The analysis of incoming T1MES datasets is carried out using a MATLAB graphical user interface. From the data, mean  $T_1$  and  $T_2$  values were measured from each of the nine contrast tubes. Using the ROI measurement tool in MATLAB, mean signal intensity of the central 50 % area of each of the nine tubes was calculated.

## Results

### Model predictions of $T_1$ and $T_2$

Linear models for longitudinal and transverse relaxation rates  $R_1|R_2$  in terms of the ingredients agarose and  $\text{NiCl}_2$  can be written following similar work previously published [14]:

$$R_x/\text{ms}^{-1} = a_x + b_x C_{w,\text{agarose}}/\% + c_x C_{\text{Ni}^{2+}}/\text{mM}$$

where  $x = 1, 2$ ,  $C_{w,\text{agarose}}$  and  $C_{\text{Ni}^{2+}}$  are the weight and molar concentration of agarose and  $\text{Ni}^{2+}$ , respectively, and  $a_x$ ,  $b_x$  and  $c_x$  are found by surface fitting (Fig. 5):

$$a_1 = 3.750 \times 10^{-4}, \quad b_1 = 8.790 \times 10^{-6}, \quad c_1 = 6.683 \times 10^{-4}$$

$$a_2 = 1.645 \times 10^{-4}, \quad b_2 = 7.622 \times 10^{-3}, \quad c_2 = 7.201 \times 10^{-4}$$

From these relationships and replacing relaxation rate  $R_x$  by relaxation time  $T_x$  we calculated the required agarose % (by weight) and  $\text{Ni}^{2+}$  concentrations (equal to added molar concentration of  $\text{NiCl}_2 \cdot 6\text{H}_2\text{O}$  as it is highly dissociated) for each of the 13 tube stock solutions as shown in Table 2.

The presented model was accurate within the root-mean-square errors (RMSE) in Fig. 5 caption over the range  $T_1 = 300\text{--}1900$  ms and  $T_2 = 40\text{--}300$  ms that cover the range of relaxation times expected in healthy and diseased myocardium pre- and post-GBCA.

### Reference $T_1$ and $T_2$ values

Comparison of 'gold standard'  $T_1$  and  $T_2$  values (Fig. 6) between the ten E-model phantoms tested, confirmed reproducibility of manufacturing. Across the 9 tubes, CoV for  $T_1$  ranged from 0.17 to 1.25 % at 1.5 T and 0.08 to 1.0 % at 3 T, while  $T_2$  ranged from 0.74 to 2.12 % at 1.5 T and 0.40 to 1.72 % at 3 T.

### $B_0$ uniformity

Final phantoms were free of air bubbles and susceptibility artifacts at both field strengths.  $T_1$  maps were obtained in the specified mid-phantom slice at the specified scan setup, and were free from off-resonance artifacts (Fig. 2i, j). Provided the bottle was placed coaxial with  $z$ -axis, imaged as

a transverse slice halfway along, and with the use of shimming as specified in the T1MES manual,  $B_0$  uniformity was delivered (Fig. 7a) to within  $\pm 30$  Hz at 3 T.

### $B_1$ uniformity

The compact HDPE beads ( $\sim 1$  kg of compact pellets per phantom bottle) adequately flattened the  $B_1$  field at 3 T (Fig. 7b), compared to the PMMA microbeads, sucrose and sodium chloride. The HDPE beads cause a speckle of dark regions in the gel matrix as they generate no MR signal that is normally detectable. The beads are expected to have similar diamagnetism to the gel so they have no impact on the  $B_0$  field.

### Temperature dependency experiments

Collectively the results (Fig. 8) by slow SE scanning methods show that over the range  $15\text{--}30^\circ\text{C}$  the short- $T_1$  tubes are more stable with temperature than the long- $T_1$  tubes where  $T_1$  increased more strongly with temperature.  $T_2$  values also change significantly with temperature (Fig. 8b), decreasing as temperature increases.


### Short-term reproducibility

**Test 1:** Six loose tubes as used in the 1.5 T E-model (Fig. 9) showed a CoV of  $\leq 1$  % for both  $T_1$  and  $T_2$  reproducibility. Tube B with the longest  $T_1$  and  $T_2$  showed the greatest variability between repeated scans.

**Test 2:** Test-retest evaluation of one of the final phantoms for 3 T by cardiac  $T_1$  mapping, including complete repositioning and readjustments, also gave a short-term repeatability CoV for  $T_1 \leq 1$  % (Table 3 detailing results for 3 T). For  $T_2$  measured by fast  $T_2$ -prepared single-shot methods, the CoV was usually below 1 % with an exceptionally large 4.1 % in the tube B with longest  $T_1$ .

### Production, distribution and initiation of trial

On 1st September 2015 the E-model T1MES phantoms (batch numbers TTP15-001 and TTP30-001 for 1.5 T and 3 T respectively) received regulatory clearance by the Food and Drug Administration (FDA) and Conformité Européenne (CE) marking as a Class I Medical Device (GMDN 40636). This initial mass manufacturing phantom experience was not always 100 % successful and important quality control lessons have been learnt: for example two different fill solutions for tubes were accidentally mislabelled initially and had to be discarded and remade; individual tubes with visible bubbles on inspection had to be corrected with appropriate procedures; any solution stock with  $T_1$  or/and  $T_2$  not falling within  $\pm 3$  % of our pre-specified targeted range had to be adjusted.



**Fig. 7**  $B_0$  and  $B_1$  field homogeneity. **a**  $B_0$  field homogeneity across the nine phantom compartments as a measure of off-resonance in Hz at 3 T (single E-model phantom results). These are extremely small shifts in frequency (30 Hz = 0.25 ppm) at 3 T and should not be regarded as significantly different between the tubes. **b** Diagonal profile of the  $B_1$  field (as per green discontinuous line in the inset) comparing relative flip angles on a Siemens 3 T system. Variance of  $B_1$  was smallest across the 9 compartments with CoV 1.54 % for HDPE beads consisting of smooth, semi-translucent, colourless compact discs (as colouring in plastics has the potential to distort the  $B_0$  magnetic field [12], see Fig. 2h) with a melt index >60 °C. We choose pellets that had not been reground, rebled or composite for this purpose. Highly monosized microbeads measured 6  $\mu$ m and were composed of crosslinked PMMA polymer. Neither microbeads, sucrose nor NaCl were comparably effective in flattening the  $B_1$  field. PMMA = poly methyl methacrylate. Other abbreviation as in Fig. 4

A total of 75 multi-vendor CMR scanners (four systems: Siemens, Philips, General Electric [GE] and Agilent) across five continents (Table 4), are currently using T1MES phantoms for their local  $T_1$  mapping QA as part of the international T1MES program. This

amounts to an initial 53 individual CMR centers and 69 devices, with six centers using the same field-specific phantom for QA scans on more than one local machine.


## Discussion

Results obtained thus far demonstrate that: 1) mass production of phantoms to regulatory standards and in accordance with a rigorously repeatable process is feasible, 2) based on the sequences used,  $T_1/T_2$  times in gels are highly reproducible in the short-term, 3) a significant temperature dependency of measured  $T_1/T_2$  values exists in tubes with longer  $T_1$  values that will require the use of a correction model.

The T1MES program seeks to advance the field of quantitative CMR relaxometry and the use of imaging biomarkers like  $T_1$  mapping and ECV in clinical trials and clinical practice. Our aim was to collaborate with industry, with leading CMR academics and clinical centers with an interest in  $T_1$  mapping, so as to develop and test a multi-center QA infrastructure, to protect normal reference data at centers and also potentially to improve consistency of  $T_1$  mapping and ECV results across imaging platforms, clinical sites, and over time. Key to the achievement of accurate and reproducible  $T_1$  mapping/ECV results in CMR is the accelerated development and adoption of rigorous hardware and software standards.

However, this proposal is subject to a further limitation that the phantoms do not model other aspects of tissues, particularly for myocardium—the magnetisation transfer [22] neither does it address the mapping techniques' ability to discriminate  $T_1$  values between adjacent regions of interest (the clinical challenge of discriminating tissue  $T_1$  values in adjacent myocardial segments). For example, the signal-to-noise ratio in the phantoms is unrealistically high as the surface coils are typically nearer; evaluating such an ability is beyond the scope of T1MES. The only realistic aim may prove to be that of providing individual (or genuinely identical) centers with a QA phantom that could protect normal reference data and assure (or even permit correction of changes in) stability of protocols during a long study.


The 1-year study, now running, is expected also to give information about gel stability. It seems reasonable to expect sudden steps in  $T_1$  values from genuine changes in the acquisition, or scatter from any remaining uncontrolled parameters or imperfect temperature correction, but there would be a gradual monotonic drift as the gel water content changes. Agarose gel is inherently unstable even within a sealed tube, because the gel contracts as water leaves it, appearing as excess water (as droplets) in the gap left by the contraction, often visible on the inner wall of the tube. Note that this effect can occur within well-sealed tubes. It is unrelated to contamination because



agarose without added nutrients does not support mould growth. Over time, this shrinkage may also occur in the matrix fill leading to air-gaps and  $B_0$  distortion, potentially occurring near the tubes making a possible contribution to an apparent drift in  $T_1$  values over time. For the first

time, the 1-year study will give large-scale initial data on the durability of this type of phantom. At study end, we aim to recall approximately 10 % of the phantoms which will be inspected for flaws in the gel using high-resolution 3D imaging, with collection also of long reference  $T_1|T_2$  data as gel drying with shrinkage and condensation into the gap is known to occur even within a sealed tube. Centers are free to keep and use the T1MES phantoms after the 1-year study ends. There is no provision for return shipment to the coordinating site, nor any knowledge of how long the gels will remain usable.

The field and temperature dependence of  $T_1$  for phantoms containing  $\text{Ni}^{2+}$  is much smaller than those containing other paramagnetic ions like  $\text{Cu}^{2+}$ . As  $T_1$  increases above 500 ms (in tubes with a low concentration of  $\text{Ni}^{2+}$ ), the tube's  $T_1$  becomes more temperature-sensitive as it is increasingly dominated by the temperature sensitive  $T_1$  of water in the gel [24, 25]. Therefore temperature monitoring of each fortnightly session is essential. Our results enable us to integrate a temperature-correction model into our multicenter T1MES analysis, that will be published at the end of the project. The temperature sensitivity of  $T_1$  revealed in the present work may not be a concern for clinical  $T_1$  mapping in healthy volunteers (as the human body is homeothermic—temperature of 37 °C) but it may be a concern for hypothermic or febrile patients. Furthermore  $T_2$  temperature dependence could also impact measured  $T_1$  as some fast- $T_1$  methods have considerable  $T_2$  sensitivity.



## Conclusion

We report on the establishment of a collaboration to develop CMR phantoms to CE/FDA standards and an

**Table 3** Short-term reproducibility experiments in a 3 T final phantom (E-model)\*

Tube	Parameter	Sequence	CoV (%)	Mean diff. $\pm$ s.d.
A	T <sub>1</sub>	pre_MOLLI_5(3)3_256_T1	0.16	255 $\pm$ 0.4
		post_MOLLI_4(1)3(1)2_256_MOCO_T1	0.18	255 $\pm$ 0.5
	T <sub>2</sub>	T2_4pt_TRUFI_192i_T2	0.66	194 $\pm$ 1.3
		T2_4pt_GRE_192i_T2	0.61	134 $\pm$ 0.8
J	T <sub>1</sub>	pre_MOLLI_5(3)3_256_T1	0.14	1860 $\pm$ 2.6
		post_MOLLI_4(1)3(1)2_256_MOCO_T1	0.17	1672 $\pm$ 2.8
	T <sub>2</sub>	T2_4pt_TRUFI_192i_T2	4.06	227 $\pm$ 9.2
		T2_4pt_GRE_192i_T2	1.37	203 $\pm$ 2.8
C	T <sub>1</sub>	pre_MOLLI_5(3)3_256_T1	0.08	460 $\pm$ 0.4
		post_MOLLI_4(1)3(1)2_256_MOCO_T1	0.08	461 $\pm$ 0.4
	T <sub>2</sub>	T2_4pt_TRUFI_192i_T2	0.52	195 $\pm$ 1.0
		T2_4pt_GRE_192i_T2	0.76	160 $\pm$ 1.2
K	T <sub>1</sub>	pre_MOLLI_5(3)3_256_T1	0.13	953 $\pm$ 1.2
		post_MOLLI_4(1)3(1)2_256_MOCO_T1	0.10	917 $\pm$ 0.9
	T <sub>2</sub>	T2_4pt_TRUFI_192i_T2	0.98	60 $\pm$ 0.6
		T2_4pt_GRE_192i_T2	0.67	49 $\pm$ 0.3
L	T <sub>1</sub>	pre_MOLLI_5(3)3_256_T1	0.08	1372 $\pm$ 1.1
		post_MOLLI_4(1)3(1)2_256_MOCO_T1	0.16	1252 $\pm$ 2.0
	T <sub>2</sub>	T2_4pt_TRUFI_192i_T2	0.91	56 $\pm$ 0.5
		T2_4pt_GRE_192i_T2	0.89	49 $\pm$ 0.4
M	T <sub>1</sub>	pre_MOLLI_5(3)3_256_T1	0.15	1178 $\pm$ 1.8
		post_MOLLI_4(1)3(1)2_256_MOCO_T1	0.12	1104 $\pm$ 1.3
	T <sub>2</sub>	T2_4pt_TRUFI_192i_T2	0.91	58 $\pm$ 0.5
		T2_4pt_GRE_192i_T2	0.66	49 $\pm$ 0.3
G	T <sub>1</sub>	pre_MOLLI_5(3)3_256_T1	0.19	285 $\pm$ 0.6
		post_MOLLI_4(1)3(1)2_256_MOCO_T1	0.20	285 $\pm$ 0.6
	T <sub>2</sub>	T2_4pt_TRUFI_192i_T2	0.29	86 $\pm$ 0.2
		T2_4pt_GRE_192i_T2	1.02	49 $\pm$ 0.5
H	T <sub>1</sub>	pre_MOLLI_5(3)3_256_T1	0.11	527 $\pm$ 0.6
		post_MOLLI_4(1)3(1)2_256_MOCO_T1	0.09	527 $\pm$ 0.5
	T <sub>2</sub>	T2_4pt_TRUFI_192i_T2	0.35	66 $\pm$ 0.2
		T2_4pt_GRE_192i_T2	0.72	46 $\pm$ 0.3
I	T <sub>1</sub>	pre_MOLLI_5(3)3_256_T1	0.06	406 $\pm$ 0.3
		post_MOLLI_4(1)3(1)2_256_MOCO_T1	0.05	409 $\pm$ 0.2
	T <sub>2</sub>	T2_4pt_TRUFI_192i_T2	0.21	72 $\pm$ 0.2
		T2_4pt_GRE_192i_T2	0.19	47 $\pm$ 0.1

\*All tests performed at  $20.3 \pm 0.48$  °C on Siemens, Skyra 3 T at RBHT, November 2015 with RR interval 900 ms and using two T<sub>1</sub> mapping sequences (pre-MOLLI 5(3)3 [256] and post-MOLLI 4(1)3(1)2 [256] with MOCO, WIPs# 780B) and two T<sub>2</sub> mapping sequences (TRUFI T2 map and GRE T2 map)  
 CoV coefficients of variation, *diff.* difference, *GRE* gradient echo, *MOCO* motion correction, *MOLLI* modified Look-Locker inversion recovery, *RR* inter-beat interval, *s.d.* standard deviation, *TRUFI* true fast imaging with steady-state free precession

initial multicenter repeat scanning program aiming for global QA of T<sub>1</sub> and ECV protocols. A rigorous and reproducible manufacturing process for the phantoms has been established. The temperature sensitivity, short-term stability and inter-phantom consistency have all been

assessed in support of the main project. An initial 69 phantoms with a multi-vendor user manual are now being scanned fortnightly in centers worldwide, permitting the academic exploration of T<sub>1</sub> mapping sequences, platform performance and stability over a year.

**Table 4** Quality assurance of T<sub>1</sub> mapping: the initial T1MES CMR centers

Center	Magnet characteristics						
	Vendor	Tesla	Name	YOM	Software	Bore <sup>b</sup> (cm)	Gradient performance <sup>c</sup>
St Thomas' Hospital UK	Siemens	1.5	Aera	2015	VE11	70	45/200
St Thomas' Hospital UK	Philips	1.5	Ingenia	2013	R4.1.3SP2	70	33/200
Oslo University Hospital Norway	Siemens	1.5	Aera	2014	VE11	70	40/200
Bristol Heart Institute UK	Siemens	1.5	Avanto	2009	VB17A	60	44/180
Diagnostikum Berlin Germany	Siemens	1.5	Aera	2015	VE11	70	45/200
GOSH UK	Siemens	1.5	Avanto	2007	VB17	60	40/180
NIH Bethesda US	Siemens	1.5	Aera	2014	VE11	70	45/200
Pittsburgh Pennsylvania US	Siemens	1.5	Esprea	2009	VB17A	70	40/200
Leiden UMC The Netherlands	Philips	1.5	Ingenia	2014	R5.1.7SP2	70	45/200
Leeds General Infirmary UK	Philips	1.5	Ingenia	2014	R5.1.7SP2	70	45/200
MUMC The Netherlands	Philips	1.5	Ingenia	2012	R 5.1.7SP2	70	45/200
Policlinico San Donato Italy	Siemens	1.5	Aera	2012	VD13A	70	45/200
Papworth UK	Siemens	1.5	Avanto	2008	VB17A	60	50/200
Wythenshawe Manchester UK	Siemens	1.5	Avanto	2008	VB17A	60	45/200
Copenhagen University Hospital Denmark	Siemens	1.5	Avanto	2008	VD13A	60	45/200
Queen Elizabeth Hospital Birmingham UK	Siemens	1.5	Avanto	2008	VB17A	60	33/125
Birmingham Children's Hospital UK	Siemens	1.5	Avanto	2010	VB17A	60	33/125
University of Kentucky USA	Siemens	1.5	Aera	2012	VD13A	70	45/200
Charles Perkins Sydney Australia	Siemens	1.5	Avanto	2013	VE17A	70	45/200
Taichung Veterans Hospital Taiwan	Siemens	1.5	Aera	2005	VE11	60	45/200
Monash Heart Australia	Siemens	1.5	Avanto	2010	VB17	55	40/200
Niguarda Hospital Milan Italy	Siemens	1.5	Avanto	2005	VB17A	60	40/200
Golden Jubilee Glasgow UK	Siemens	1.5	Avanto	2008	VB17A	60	45/200
T-TIME Multi-center phantom <sup>a</sup>							
INSERM U1044 France	Siemens		Aera	2012	VD13A	70	40/200
King Abdul-Aziz Saudi Arabia	GE	1.5	Discovery MR450	2012	DV24	60	50/200
Prince Charles Hospital Queensland	Siemens	1.5	Aera	2011	VD13A	70	45/200
Federal Medical Center Moscow	GE	1.5	Optima MR450w	2014	DV25	70	44/200
Medical University of Vienna Austria	Siemens	1.5	Avanto	2006	VD13B	60	40/200
DHZ Berlin Germany	Philips	1.5	Achieva	2008	R5.1.8	60	33/180
St George's University London UK	Siemens	1.5	Aera	2014	E11	70	45/200
RBHT London UK	Siemens	1.5	Avanto	2005	VB17A	60	40/170
University Hospital Southampton UK	Siemens	1.5	Avanto	2006	VB17A	60	40/200
Barts Heart Center London UK	Siemens	1.5	Aera	2014	VD13A	70	45/200
Barts Heart Center London UK	Siemens	1.5	Aera	2015	VE11A	70	45/200
The Heart Hospital London UK	Siemens	1.5	Avanto	2009	VD13A	70	40/200
Charité Campus Buch Germany	Siemens	1.5	Avanto	2007	VB13B	60	40/200
University of Virginia US	Siemens	1.5	Avanto	2005	VB17A	60	45/200
University of Virginia US	Siemens	1.5	Avanto	2015	VD13A	60	45/200
SIEMENS EU	Siemens	1.5	Aera	2009	VE11	70	45/200
UZ Leuven Belgium	Philips	1.5	Ingenia	2007	R5.1.7	60	45/ 200
UZ Leuven Belgium	Philips	1.5	Achieva XR	2014	R5.1.7	70	33/122
Beth Israel Deaconess Medical Center, US	Philips	1.5	Achieva	2005	R3.2	60	33/180



**Table 4** Quality assurance of T<sub>1</sub> mapping: the initial T1MES CMR centers (Continued)

NIH Bethesda US	Siemens	1.5	Aera	2012	VD13A	70	45/200
St Thomas' Hospital UK	Philips	3	Achieva TX	2007	R3.2.3	60	40/200
St Thomas' Hospital UK	Siemens	3	Biograph mMR	2013	VB20P	60	45/200
Fondazione Toscana Monasterio Pisa Italy	Philips	3	Ingenia	2012	R5.1.8	70	45/200
Oslo University Hospital Norway	Philips	3	Ingenia	2011	5.1.7	70	45/200
Oslo University Hospital Norway	Siemens	3	Skyra	2014	VE11	70	45/120
CRIC Bristol UK	Siemens	3	Skyra	2009	VD13C	60	44/180
Diagnostikum Berlin Germany	Siemens	3	Skyra	2012	VE11	70	45/200
University of Aberdeen Scotland UK	Philips	3	Achieva TX	2015	R5.1.7	60	80/100
NIH Bethesda US	Siemens	3	Verio	2009	VB17	70	33/125
Leiden UMC The Netherlands	Philips	3	Achieva TX	2012	R5.1.8.2	70	45/200
MUMC The Netherlands	Philips	3	Achieva TX	2011	R 3.2	60	40/200
Wythenshawe Manchester UK	Siemens	3	Skyra	2014	VE11	70	45/200
Copenhagen University Hospital Denmark	Siemens	3	Verio	2010	VB17	70	45/200
Charles Perkins Sydney Australia	GE	3	Discovery MR750w	2014	DV25	70	44/200
BHF Glasgow Center UK	Siemens	3	Prisma	2015	VE11	60	80/200
INSERM U1044 France	Siemens	3	Prisma	2015	VE11	60	80/200
DHZ Berlin Germany	Philips	3	Ingenia	2011	R5.1.8	70	45/200
St George's University London UK	Philips	3	Achieva TX	2012	R5.1	60	40/150
RBHT London UK	Siemens	3	Skyra PTX	2011	VD13C	70	43/180
Barts Heart Center London UK	Siemens	3	Prisma	2015	VE11	60	80/200
Leeds General Infirmary UK	Philips	3	Achieva TX	2010	R5.2	60	40/120
Montreal Heart Institute Canada	Siemens	3	Skyra	2012	VD13A	70	45/200
PTB Germany	Siemens	3	Verio	2010	VB17A	70	45/200
University of Virginia US	Siemens	3	Skyra	2011	VE11A	70	45/200
UZ Leuven Belgium	Philips	3	Ingenia	2010	R5.1.7	70	45/200
NIH Bethesda US	Siemens	3	Skyra	2012	VD13A	70	45/200
University of Queensland Australia	Siemens	7	Magnetom 7	2013	VB17B	60	72/200
University of Queensland Australia	Siemens	3	Trio TIM	2008	VB17A	60	45/200
Glenfield Hospital Leicester UK	Siemens	3	Skyra	2010	VD13A	70	45/200
Baker IDI Australia	Siemens	3	Prisma	2014	VD13D	60	80/200
NIST US <sup>d</sup>	Agilent	1.5	Varian	2013	VnmrJ 4	14	300/475
NIST US <sup>d</sup>	Agilent	1.5	Varian	2013	VnmrJ 4	14	300/475

<sup>a</sup>This phantom is a gift to support the ongoing 'T-TIME' study. It will be scanned across multiple UK centers

<sup>b</sup>Inner diameter i.e. around patient

<sup>c</sup>Maximum gradient performances as returned on the T1MES registration forms by each site. These values are subject to many modifying conditions. More relevant parameters such as TR and TE will be extracted from uploaded Digital Imaging and Communications in Medicine (DICOM) images where this is possible from DICOM

<sup>d</sup>Loose tubes only for 1.5 T and 3 T

YOM year of manufacture

## Additional file

**Additional file 1:** The T1MES User Manual. (PDF 13350 kb)

## Abbreviations

CE: Conformité Européenne; CoV: Coefficients of variation; Cu<sup>2+</sup>: Copper ions; DICOM: Digital imaging and communications in medicine; ECV: Extracellular volume; FA: Flip angle; FDA: Food and Drug Administration; GBCA: Gadolinium-based contrast agents; GE: General electric; HDPE: High-

density polyethylene; Hz: Hertz; IRSE: Inversion recovery spin echo; LCD: Liquid crystal display; Mn<sup>2+</sup>: Manganese ions; MOLL: Modified look-locker inversion recovery; MR: Magnetic resonance; NaCl: Sodium chloride; Ni<sup>2+</sup>: Nickel ions; NiCl<sub>2</sub>: Nickel chloride; NMR: Nuclear magnetic resonance; PMMA: Poly methyl-methacrylate; QA: Quality assurance; R<sub>1</sub>/R<sub>2</sub>: Relaxivity of T<sub>1</sub> and T<sub>2</sub>; RF: Radiofrequency; RMSE: Root-mean-square error; ROI: Region of interest; RR: Inter-beat interval; SAR: Specific absorption rate; SASHA: Saturation recovery single-shot acquisition; SE: Spin echo; ShMOLL: Shortened modified Look-Locker inversion recovery sequence; T<sub>1</sub>/T<sub>2</sub>: T<sub>1</sub> and T<sub>2</sub>; TE: Echo time; TI: Inversion time; TR: Repetition time

## Acknowledgements

The authors are indebted to all the staff of Resonance Health and to scientists and physicists at St. Thomas' Hospital, in particular Dr Amedeo Chiribiri. They are also indebted to Siemens Healthcare GmbH (Dr Andreas Greiser, Dr Carmel Hayes, Dr Shivravan Giri), Philips (Dr David Higgins) and GE Healthcare (Dr Glenn Slavin and Dr Anja Brau) for their ongoing advice.

## Funding

This project has been funded by a European Association of Cardiovascular Imaging (EACVI part of the ESC) Imaging Research Grant, a UK National Institute of Health Research (NIHR) Biomedical Research Center (BRC) Cardiometabolic Research Grant at University College London (UCL, #BRC/199/JM/101320), and a Barts Charity Research Grant (#1107/2356/MRC0140). G.C. is supported by the National Institute for Health Research Rare Diseases Translational Research Collaboration (NIHR RD-TRC) and by the NIHR UCL Hospitals Biomedical Research Center. J.C.M. is directly and indirectly supported by the UCL Hospitals NIHR BRC and Biomedical Research Unit at Barts Hospital respectively. This work was in part supported by an NIHR BRC award to Cambridge University Hospitals NHS Foundation Trust and NIHR Cardiovascular Biomedical Research Unit support at Royal Brompton Hospital London UK.

## Availability of data and materials

A supplementary material is now provided with detailed information about the T1MES analysis procedure and setup instructions.

## Authors' contributions

JCM, PG and GC developed the concept and approach; PK provided crucial scientific advice, computational scripts and graphical user interfaces that permitted T1MES data analysis; GC, PG and JCM wrote the manuscript; PG and GC performed phantom design experiments in London; JD provided methodological insights; WP, AB and CR oversaw the mass production and technical development of phantoms in Australia; WP and FGH performed temperature experiments in Australia; GC performed the statistical analysis; FGH and WP performed the model curvefitting for tube recipes; GC, RBo, RJE, CT and GB contributed to analysis of international phantom datasets. PK, KEK, RBr, MP, MJG, BI, RN and MS performed phantom experiments on prototypes in the expert centers, participated in data interpretation, study design and contributed to the manuscript; all authors reviewed and approved the final manuscript.

## Authors' information

This is all reported in the title page including author degrees, affiliations, emails and titles. The manuscript has neither been published nor is currently under consideration for publication by any other journal. All named authors have seen and approved the final version.

## Competing interests

An industrial group (Resonance Health) is being funded to mass-produce the described T1MES phantoms to CE mark/FDA standards to permit international distribution in the T1MES academic program. No financial or non-financial competing interests exist for any of the authors.

## Consent for publication

Not applicable - As this research did not involve human participants there is no consent for publication required. All authors have read and approved the final manuscript for publication.

## Ethics approval and consent to participate

Not applicable - As this research did not involve human participants there is no ethical approval to report.

## Author details

<sup>1</sup>UCL Biological Mass Spectrometry Laboratory, Institute of Child Health and Great Ormond Street Hospital, 30 Guilford Street, London, UK. <sup>2</sup>NIHR University College London Hospitals Biomedical Research Center, Maple House Suite, Tottenham Court Road, London W1T 7DN, UK. <sup>3</sup>Barts Heart Center, St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK. <sup>4</sup>CMR Department, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK. <sup>5</sup>National Institutes of Standards and Technology (NIST), Boulder, MS 818.03, 325 Broadway, Boulder, CO 80305-3337, USA. <sup>6</sup>Biomagnetics

Group, School of Physics, University of Western Australia, 35 Stirling Hwy, Crawley, WA 6009, Australia. <sup>7</sup>NeuroImaging group, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, P.O. Box 217, 7500 AE Enschede, Netherlands. <sup>8</sup>Physikalisch-Technische Bundesanstalt (PTB), Abbestr. 2 – 12, D-10587, Berlin, Germany. <sup>9</sup>Cardiology, Charité, Medical Faculty of Humboldt-University Berlin ECRC and HELIOS Clinics, Berlin, Germany. <sup>10</sup>Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. <sup>11</sup>Department of Physics, Imperial College London, Prince Consort Rd, London SW7 2BB, UK. <sup>12</sup>University of Milan-Bicocca, Piazza dell'Ateneo Nuovo 1, 20100 Milan, Italy. <sup>13</sup>San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy. <sup>14</sup>Department of Clinical Biochemistry, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK. <sup>15</sup>Cardiovascular Biomedical Research Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK. <sup>16</sup>Resonance Health, 278 Stirling Highway, Claremont, WA 6010, Australia. <sup>17</sup>Department of Medicine (Cardiovascular Division) Beth Israel Deaconess Medical Center, Harvard Medical School, Cardiology East Campus, Room E/SH455, 330 Brookline Ave, Boston, MA 02215, USA. <sup>18</sup>University of Virginia Health System, 1215 Lee St, PO Box 800158, Charlottesville, VA 22908, USA. <sup>19</sup>National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Drive, Building 10, Room B1D416, MSC1061, Bethesda, MD 20892-1061, USA. <sup>20</sup>UCL Institute of Cardiovascular Science, University College London, Gower Street, London WC1E 6BT, UK.

Received: 30 March 2016 Accepted: 2 September 2016

Published online: 22 September 2016

## References

1. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, Gatehouse PD, Arai AE, Friedrich MG, Neubauer S, Schulz-Menger J, Schelbert EB. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. *J Cardiovasc Magn Reson*. 2013;15:92.
2. Kellman P, Arai AE, Xue H. T1 and extracellular volume mapping in the heart: estimation of error maps and the influence of noise on precision. *J Cardiovasc Magn Reson*. 2013;15:56.
3. Kellman P, Hansen MS. T1-mapping in the heart: accuracy and precision. *J Cardiovasc Magn Reson*. 2014;16:2.
4. Raman FS, Kawel-Boehm N, Gai N, Freed M, Han J, Liu C-Y, Lima JA, Bluemke DA, Liu S. Modified look-locker inversion recovery T1 mapping indices: assessment of accuracy and reproducibility between magnetic resonance scanners. *J Cardiovasc Magn Reson*. 2013;15:64.
5. Messroghli DR, Greiser A, Fröhlich M, Dietz R, Schulz-Menger J. Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. *J Magn Reson Imaging*. 2007;26:1081–6.
6. Gai ND, Stehning C, Nacif M, Bluemke DA. Modified Look-Locker T1 evaluation using Bloch simulations: Human and phantom validation. *Magn Reson Med*. 2013;69:329–36.
7. Tofts PS. Standing waves in uniform water phantoms. *J Magn Reson*. 1994; 104:143–7.
8. Kuchel PW, Chapman BE, Bubbs WA, Hansen PE, Durrant CJ, Hertzberg MP. Magnetic susceptibility: Solutions, emulsions, and cells. *Concepts Magn Reson*. 2003;18A:56–71.
9. Freed DE. Dependence on chain length of NMR relaxation times in mixtures of alkanes. *J Chem Phys*. 2007;126:174502.
10. Christofferson JO, Olsson LE, Sjöberg S. Nickel-doped agarose gel phantoms in MR imaging. *Acta radiol*. 1991;32:426–31.
11. Mitchell MD, Kundel HL, Axel L, Joseph PM. Agarose as a tissue equivalent phantom material for NMR imaging. *Magn Reson Imaging*. 1986;4:263–6.
12. Keenan K, Stupic K, Horneber E, Boss M, Russek S. Paramagnetic ion phantom to independently tune T1 and T2. *Proc from ISMRM 23rd Annu Meet Exhib*. 2015, Abstract.
13. Kraft KA, Fatouros PP, Clarke GD, Kishore PR. An MRI phantom material for quantitative relaxometry. *Magn Reson Med*. 1987;5:55–62.
14. Yoshida A, Kato H, Kuroda M, Hanamoto K. Development of a phantom compatible for MRI and hyperthermia using carrageenan gel — relationship between T1 and T2 values and NaCl concentration. *Int J Hyperther*. 2004;8: 803–14.

15. Kellar KE, Briley-Saebo K. Phantom standards with temperature- and field-independent relaxation rates for magnetic resonance imaging. *Invest Radiol*. 1998;33:472–9.
16. Koenig SH, Brown RD. Relaxation of solvent protons by paramagnetic ions and its dependence on magnetic field and chemical environment: implications for NMR imaging. *Magn Reson Med*. 1984;1:478–95.
17. Vassiliou V, Heng E, Donovan J, Greiser A, Babu-Narayan SV, Gatzoulis MA, Firmin D, Pennell DJ, Gatehouse P, Prasad SK. Longitudinal stability of gel T1 MRI Phantoms for quality assurance of T1 mapping. *J Cardiovasc Magn Reson*. 2015;17 Suppl 1:W28.
18. Kellman P, Herzka DA, Arai AE, Hansen MS. Influence of off-resonance in myocardial T1-mapping using SSFP based MOLLI method. *J Cardiovasc Magn Reson*. 2013;15:63.
19. Hernando D, Kellman P, Halder JP, Liang Z. Robust water/fat separation in the presence of large field inhomogeneities using a graph cut algorithm. *Magn Reson Med*. 2010;63:79–90.
20. Tofts PS, Barker GJ, Dean TL, Gallagher H, Gregory AP, Clarke RN. A low dielectric constant customized phantom design to measure RF coil nonuniformity. *Magn Reson Imaging*. 1997;15:69–75.
21. Webb A. Optimizing the point spread function in phase-encoded magnetic resonance microscopy. *Concepts Magn Reson*. 2004;22A:25–36.
22. Robson MD, Piechnik SK, Tunnicliffe EM, Neubauer S. T1 measurements in the human myocardium: The effects of magnetization transfer on the SASHA and MOLLI sequences. *Magn Reson Med*. 2013;70:664–70.
23. Captur G, Gatehouse P, Pang W, Royet C, Moon J. T1MES user manual. 2015. Download link: <https://redcaphh.c-cloudservices.net/surveys/?s=dRcYg3HGz5> 2015.
24. Simpson JH, Carr HY. Diffusion and nuclear spin relaxation in water. *Phys Rev*. 1958;111:1201–2.
25. Tofts P. Quality assurance, accuracy, precision and phantoms. In: Tofts P, editor. In Chapter 3: Quantitative MRI of the brain: measuring changes caused by disease. Chichester: John Wiley; 2003. p. 55–81.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

